Shares of Quest Diagnostics (DGX) are soaring 5.02% in Tuesday's pre-market trading session following the company's announcement of better-than-expected second-quarter results and an upward revision of its full-year 2025 guidance. The laboratory operator's strong performance is attributed to robust demand for its diagnostic testing services and operational efficiency improvements.

Quest Diagnostics reported adjusted earnings per share of $2.62 for the second quarter, surpassing the Wall Street consensus estimate of $2.57. The company's revenue for the quarter reached $2.76 billion, marking a 15.2% increase from the same period last year and beating analyst expectations of $2.73 billion. This impressive growth was driven by a 5.2% increase in organic revenues, reflecting the sustained demand for clinical solutions and expanded business from enterprise accounts.

In light of its strong performance and continued positive utilization trends, Quest Diagnostics has raised its full-year 2025 guidance. The company now expects adjusted earnings per share to be between $9.63 and $9.83, up from the previous range of $9.55 to $9.80. Additionally, the annual revenue forecast has been increased to $10.80 billion - $10.92 billion, compared to the earlier projection of $10.70 billion - $10.85 billion. CEO Jim Davis highlighted the company's success in deploying automation and digital technologies across operations, which has resulted in significant productivity gains. The raised outlook reflects management's confidence in Quest's ability to capitalize on the growing demand for diagnostic services and maintain its operational efficiency.